News

All five companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition Boehringer Ingelheim and Eli Lilly and Company were required to issue a corrective statement.

All four companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition Stirling Anglian was required to issue a corrective statement.

Both companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition Astellas UK Limited and Astellas Europe have been required to issue corrective statements and have been publicly reprimanded. Both companies have been required to undergo audits and Astellas UK has been suspended from membership of the ABPI.

AstraZeneca and Genzyme have been named in advertisements following breaches of the ABPI Code of Practice for the Pharmaceutical Industry.¹

Today the Association of the British Pharmaceutical Industry is publishing details of payments and other benefits in kind made by the industry to healthcare professionals, healthcare organisations and other relevant decision makers.

Astellas UK is suspended from membership of the ABPI

The arrangements for advisory board meetings are often the subject of enquiries to the PMCPA for informal advice.

Both companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry.

In 2016 pharmaceutical companies will disclose details of certain transfers of value made to healthcare professionals (HCPs), other relevant decision makers (ORDMs) and healthcare organisations (HCOs) during 2015 on the ABPI central platform.

The PMCPA has issued informal guidance on certification which examines in particular the requirements in relation to projects involving a number of companies and which reflects the changes in the 2016 ABPI Code.

The new Interactive version of the 2016 ABPI Code of Practice for the pharmaceutical industry is available on the PMCPA website from today. 

The 2016 Code can be downloaded here